-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson announced that the US FDA approved RYBREVANT FASPRO™ as the first and only dual-targeted therapy for advanced head and neck cancer.

Zhitongcaijing·11/06/2026 02:09:02
Listen to the news
Johnson & Johnson announced that the US FDA approved RYBREVANT FASPRO™ as the first and only dual-targeted therapy for advanced head and neck cancer.